New pill targets brain tumor metabolism in early trial

NCT ID NCT06636162

Recruiting now Knowledge-focused Sponsor: Washington University School of Medicine Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early phase 1 trial is testing an oral drug called DSP-0390 in 20 people with IDH-mutant gliomas who are scheduled for tumor removal surgery. The goal is to see how much of the drug gets into the brain tumor and blood, and whether it affects cholesterol-related pathways. Participants take the drug for about two weeks before surgery, and tissue and blood samples are collected to measure drug levels and biological changes.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: DSP-0390 (oral drug)
What this could lead to: If successful, this could point toward a new treatment option for IDH-mutant gliomas by targeting cholesterol metabolism.
What could go wrong: This is a very early, small study (20 people) focused on drug levels and safety, not on curing or shrinking tumors. It may not lead to an effective treatment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for GLIOMA, MALIGNANT are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

brain cancer glioblastoma glioma grade II glioma grade III glioma malignant glioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

GLIOMA, MALIGNANT GRADE II GLIOMA IDH MUTATION

Contacts and locations

Locations

Washington University School of Medicine
RECRUITING

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.